Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
SANTA CLARA, CA, April 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Shockwave Medical, Inc. (NASDAQ: SWAV) (“Shockwave”), a pioneer in the development of Intravascular Lithotripsy (IVL) to...
VANCOUVER and MINNEAPOLIS, MN, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth...
VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive...
VANCOUVER and MINNEAPOLIS, Feb. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. (“Neovasc” or “the Company”) (NASDAQ , TSX : NVCN) today announced the German Institute for the...
VANCOUVER, BC, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ,TSX: NVCN), a leader in the development of minimally invasive devices for...
VANCOUVER and MINNEAPOLIS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced an update on the COSIRA-II Clinical...
VANCOUVER and MINNEAPOLIS, Nov. 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that European Heart Journal - Case...
VANCOUVER and MINNEAPOLIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the third...
VANCOUVER and MINNEAPOLIS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Centers for Medicare and...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 40.15 | 40.15 | 40.15 | 0 | 0 | CS |
| 4 | 0 | 0 | 40.15 | 40.15 | 40.15 | 0 | 0 | CS |
| 12 | 0 | 0 | 40.15 | 40.15 | 40.15 | 0 | 0 | CS |
| 26 | 0 | 0 | 40.15 | 40.15 | 40.15 | 0 | 0 | CS |
| 52 | 0 | 0 | 40.15 | 40.15 | 40.15 | 0 | 0 | CS |
| 156 | 39.62 | 7475.47169811 | 0.53 | 41.2 | 0.365 | 2088 | 4.38524687 | CS |
| 260 | 35.98 | 862.829736211 | 4.17 | 41.2 | 0.365 | 26026 | 1.87282944 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
